CW August 2005Issue Number 8 August 2005 ISSN 10593802 Clinical Trials for a Promising Anti-Cancer DrugResults from three phase II trials indicate that an investigational agent called temsirolimus, a derivative of rapamycin, has antitumor activity in varieties of deadly cancers.
Go to Previous Page Go to Next Page Source & Additional Reading Journal of Clinical Oncology, August 10, 2005. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW August 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |